Essen / Junan. Evonik and the Fufeng Group have entered into a cooperation agreement for the production of ThreAMINO® (L-threonine). The renowned Chinese specialist in bio-fermentation will toll manufacture ThreAMINO® for Evonik using Evonik’s technology. This strategic partnership supports Evonik’s positioning and efficiency in the animal nutrition segment. For the first time, Evonik is now able to offer ThreAMINO® worldwide with a lean asset footprint.
"Our strategy reflects the recent dynamics of the feed amino acids market and helps Evonik to further optimize its bio amino acid business. The agreement with Fufeng enables us to provide our full portfolio of amino acids to all of our customers. This way, we’re supporting our position in Western and Asian markets and transforming our business model by focusing on our value creating strengths in sales, services and technology”, says Dr. Emmanuel Auer, Head of the Animal Nutrition Business Line at Evonik. For all customers, supply security, product quality and personal contacts remain the same.
"This collaboration is a good example of how two strong partners join forces. By working together, we build the foundation for a long-lasting and trusting strategic partnership", says Zhao Qiang, CEO of Fufeng Group.
The Junan-based Fufeng Group operates several large-scale production facilities in Northern China and counts as the world’s largest producer of starch-based food and feed ingredients with a strong record of manufacturing fermentative feed additives. The collaboration with Evonik enables Fufeng to assume an important role in supplying amino acids.
L-Threonine, marketed as ThreAMINO® by Evonik, is an essential amino acid that the body cannot produce itself. It must therefore be taken up by the animals with the feed. An optimal L-threonine level improves feed intake, weight gain and nutritional value of the feed. In contrast, nitrogen excretion decreases because the crude protein content of the feed is balanced according to the nutrient requirements of the animals.
Evonik has over 60 years of experience in the production of essential amino acids and provides solutions for efficient and sustainable animal nutrition to customers in over one hundred countries around the world. By expanding its range of innovative feed additives beyond amino acids, Evonik wants to make an even greater contribution to the efficiency of animal feed and create additional value for its customers. Evonik's animal nutrition products and services play a key role worldwide in producing healthy and affordable food while conserving natural resources and reducing its environmental footprint.
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2016, the enterprise generated sales of around €12.7 billion and an operating profit (adjusted EBITDA) of about €2.165 billion.
About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 7,500 employees, and generated sales of around
€4.3 billion in 2016.
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.